https://endpts.com/fda-adcomm-votes-in-favor-of-first-drug-for-agitation-associated-with-alzheimers-dementia/
0
0
4/14/23 at 7:46pm
Organization
Endpoints News
Author
Zachary Brennan
A joint meeting of two FDA adcomms on Friday voted 9-1 in favor of Otsuka and Lundbeck’s drug Rexulti (brexpiprazole) for agitation associated with Alzheimer's dementia (AAD). First approved in 2015 for schizophrenia and as an an adjunctive therapy to antidep…
Create an account
or login to join the discussion